MedTrace Logo

Long Term Safety Trial of z102 and Prednisone in Patients With Moderate to Severe Rheumatoid Arthritis

NCT01612377 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2012-09-11

No results posted yet for this study

Summary

This study will compare an experimental drug called Z102 (combination of prednisolone and dipyridamole, against prednisone 5mg and prednisone 7.5mg in patients with moderate to severe Rheumatoid Arthritis for a period of 52 weeks.

Conditions

Interventions

DRUG

Prednisolone-Dipyridamole

Oral, QD

DRUG

Prednisone

Oral QD Prednisone 5mg

DRUG

prednisone

Oral, QD prednisone 7.5mg

Sponsors & Collaborators

  • Zalicus

    lead INDUSTRY

Principal Investigators

  • Gene Wright, PHARM.D, PH.D · Zalicus, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2013-07-31
Completion
2013-09-30

Countries

  • Serbia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01612377 on ClinicalTrials.gov